However, the predictive performance of ultrasomics in assessing the response to TKI combined anti-PD-1 antibody therapy for advanced HCC patients has been rarely studied, this study intends to explore this, developing and validating a machine learning-based ultrasomic model to predict the objective response of patients with unresectable HCC to TKI combined with PD-1 antibody therapy, in order to provide novel therapeutic options for who were intermediate- to advanced stage liver cancer patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.